Disease & disorder

ankylosing spondylitis

MONDO:0005306

An autoimmune chronic inflammatory disorder characterized by inflammation in the vertebral joints of the spine and sacroiliac joints. It predominantly affects young males. Patients present with stiffness and pain in the spine.

Clinical trials109
Recruiting9
Drug concepts studied7
Synonyms1

Research intelligence

Directly mapped studies only · unique clinical trials

Current registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.

Medications under investigation

Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.

Loading mapped interventions…

MONDO disease family

Loading verified ontology relationships…

Recruiting studies by city

Loading research-site locations…

Trial status

Loading…

Trial phase

Loading…

Study start year

Loading…

Investigated drug interventions

Loading…
Background context

Ankylosing spondylitis

Ankylosing spondylitis (AS) is a type of arthritis from the disease spectrum of axial spondyloarthritis. The term comes from the Greek ankylos meaning crooked, curved or rounded, spondylos meaning vertebra, and -itis meaning inflammation. It is characterized by long-term inflammation of the joints of the spine, typically where the spine joins the pelvis. Lower back pain is a hallmark, but eye and gastrointestinal problems and arthritis of other joints may also occur. Joint mobility in the affected areas often worsens over time, though the progression of symptoms varies significantly. Ankylosing spondylitis is believed to involve a combination of genetic and environmental factors. More than 90% of people affected in the UK have a specific human leukocyte antigen known as the HLA-B27 antigen, though the genetic correlation varies across populations (e.g., only 70% of AS patients in Turkey are HLA-B27 positive). The underlying mechanism is believed to be autoimmune or autoinflammatory. Diagnosis is based on symptoms with support from medical imaging and blood tests. AS is a type of seronegative spondyloarthropathy, meaning that tests show no presence of rheumatoid factor (RF) antibodies. As of 2019, there is no cure for AS. Treatments may include medication, physical therapy, and surgery. Medication therapy focuses on relieving the pain and other symptoms of AS, as well as stopping the disease progression by counteracting long-term inflammatory processes. Commonly used medications include NSAIDs, TNF inhibitors, IL-17 antagonists, and DMARDs. Glucocorticoid injections are o...

Background only. Canonical identity remains MONDO; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

40 shown
Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory DiseasesNCT06842316 · 2025-04-10
RECRUITING
Rheumatology Diet StudyNCT06339957 · 2024-03-01
RECRUITING
Safety and Efficacy of Capsule FMT in Treatment-naïve Patients With Newly Diagnosed Chronic Inflammatory DiseasesNCT04924270 · 2023-12-13
RECRUITING
IMPACT - AndHealth Autoimmune Research RegistryNCT05883371 · 2023-06-08
RECRUITING
Biomarkers in Inflammatory Rheumatic Diseases DiagnosisNCT06778343 · 2023-01-31
RECRUITING
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint InhibitorsNCT04751396 · 2022-04-20
RECRUITING
Rheumatology Patient Registry and BiorepositoryNCT04402086 · 2020-08-04
RECRUITING
Korean College of Rheumatology Biologics and Targeted Therapy RegistryNCT01965132 · 2012-12-01
RECRUITING
Exactech Shoulder Post Market Clinical Follow-up StudyNCT05603728 · 2007-07-19
RECRUITING
Pain Phenotyping of Rheumatic Diseases - An Observational StudyNCT07829497 · 2026-10-12
NOT_YET_RECRUITING
Ocular Surface Changes and Meibomian Gland Dysfunction in Rheumatologic PatientsNCT07810569 · 2026-10-01
NOT_YET_RECRUITING
Skin Autofluorescence Assessment of Advanced Glycation End Products in Rheumatic DiseasesNCT07329556 · 2026-01-15
NOT_YET_RECRUITING
Activating the Cholinergic Anti-Inflammatory Pathway in Healthy Volunteers and People With Inflammatory ArthritisNCT06555562 · 2025-10-01
COMPLETED
Mass Spectrometry-based Immune Profiling in Autoimmune DiseasesNCT07188285 · 2025-05-25
ENROLLING_BY_INVITATION
Artificial Intelligence Literacy and E-Health Literacy in Rheumatic DiseasesNCT07054749 · 2024-12-22
COMPLETED
Construct Validity and Responsiveness of EQ-5D-3L in Patients With Rheumatic DiseaseNCT06568029 · 2024-08-16
COMPLETED
Integration of Remote Monitoring in the Management of Chronic Immunosuppressive TherapyNCT06544343 · 2024-07-01
UNKNOWN
Construct Validity and Responsiveness of EQ-5D-3L and EQ-5D-5L in Patients With Inflammatory Joint DiseaseNCT07580092 · 2023-11-30
COMPLETED
Study of Gynecological Follow-up of Patients With Autoimmune Disease or Inflammatory RheumatismNCT05961267 · 2023-07-24
COMPLETED
Impact of Air Pollution on the Course of Inflammatory RheumatismNCT05862584 · 2023-05-26
COMPLETED
Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic DiseasesNCT05879419 · 2023-05-23
ACTIVE_NOT_RECRUITING
Rheumatology-based Adaptive Intervention for Social Determinants and Health EquityNCT05715463 · 2023-03-01
ACTIVE_NOT_RECRUITING
An Observational, Prospective Study to Assess the Efficacy and Safety of Adalloce in Patients With RA and ASNCT05835518 · 2023-01-26
UNKNOWN
A Study to Evaluate the Safety of Remsima® SC in the Treatment of RA, AS, PsA and PsNCT05866614 · 2023-01-13
ACTIVE_NOT_RECRUITING
The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.NCT05913817 · 2023-01-09
COMPLETED
A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune DiseaseNCT06587828 · 2023-01-03
COMPLETED
SAPHIR : Assessment of Predictive Factors for Persistence of Treatment After Initiation of Adalimumab With a Biosimilar (Adalimumab Fresenius KaBI or Substitution of Reference Adalimumab With the Fresenius Kabi Adalimumab Biosimilar in Patients With Chronic Inflammatory DiseasesNCT05598684 · 2022-11-24
UNKNOWN
The Effects of Jing Si Herbal Tea Liquid Packets on Fatigue in Patients With Inflammatory ArthritisNCT05257174 · 2022-06-15
UNKNOWN
Yuflyma® (Adalimumab), Patient Experience After SwitchingNCT05427942 · 2022-06-03
UNKNOWN
bIosimilar of aDalimumab, an European evAluationNCT05190484 · 2022-04-30
UNKNOWN
Therapeutic Response to Tumor Necrosis Factor-alpha (TNF-alpha) Antagonists in Rheumatoid Arthritis.NCT05379049 · 2022-03-01
UNKNOWN
Survey About Diet in Chronic Inflammatory Rheumatic DiseasesNCT05283096 · 2022-02-10
UNKNOWN
Vaccination Perception in Inflammatory Conditions - Flu, Pneumonia and COVID-19NCT05115370 · 2021-11-01
COMPLETED
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research InitiativesNCT05635266 · 2021-10-26
UNKNOWN
The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech RepublicNCT05098600 · 2021-10-15
COMPLETED
Compare the Effect of Eupatilin and Rebamipide on the Prevention of GastroenteropathyNCT04885751 · 2021-06-01
UNKNOWN
COVID-19 Vaccination in Rheumatic Disease PatientsNCT04839315 · 2021-02-15
TERMINATED
The Relationship Between Inflammatory ARTritis and CArdiac DIseAseNCT05647577 · 2021-01-01
ACTIVE_NOT_RECRUITING
Seroprevalence Study of CoV-2-SARS (COVID-19) Infection in Patients With Chronic Inflammatory Rheumatic DiseasesNCT04655612 · 2020-12-01
COMPLETED
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia AreataNCT04239521 · 2020-10-01
COMPLETED

Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.